Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in ESR1 and PIK3CA from ctDNA were assayed in clinical trial samples from ER+ metastatic breast cancer patients randomized either to the SERD fulvestrant or fulvestrant plus a pan-PI3K inhibitor. ESR1 mutations are present in 37% of baseline samples and are enriched in patients with luminal A and PIK3CA -mutated tumours. ESR1 mutations are often polyclonal and longitudinal analysis shows distinct clones exhibiting divergent behaviour over time. ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free survival is not different in patients with ESR1 mutations compared with wild-type patients. ESR1 mutations are not associated with clinical resistance to fulvestrant in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The gain-of-function ERα LBD mutations are frequently found in metastatic endocrine-resistant breast cancers (Jeselsohn et al., 2014; Robinson et al., 2013; Spoerke et al., 2016; Toy et al., 2013; Zhang et al., 1997) and recruit elevated levels of the SRC coactivators to EREs (Gates et al., 2018).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Spoerke et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“Patients whose tissue was collected after receiving AI therapy shown on the left (21), and those whose tissue was collected before AI”
BackgroundThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Research works printed but not linked: 1
- Krop, I. E. et al. Phase 2 randomised study of the PI3-kinase inhibitor pictilisib plus fulvestrant versus placebo plus fulvestrant in patients with oestrogen receptor-positive, aromatase inhibitor-resistant advanced or metastatic breast cancer: the FERGI trial. Lancet Oncol (in the press).
Cited by
Items 201–300 of 314
Bui, T. B. V., Burgering, B. M. T., Goga, A., Rugo, H. S., & Veer, L. V. ‘. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00473 · Cited by 15
“Besides interpatient heterogeneity, it is known that advanced breast cancers may also develop high intratumoral heterogeneity, which could result from tumor evolution in response to therapy and contribute to therapy resistance.(72) Non-/slow-proliferative (quiescent) populations are generally thought to be more resist…”
BackgroundFOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1 -Mutant Breast Cancer
Wu, Y., Li, Z., Wedn, A. M., Casey, A. N., Brown, D. D., Rao, S. V., Omarjee, S., Hooda, J., Carroll, J. S., Gertz, J., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0516 · Cited by 15
Corné, J., Quillien, V., Callens, C., Portois, P., Bidard, F., Jeannot, E., Godey, F., Du, F. L., Robert, L., Bourien, H., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117366 · Cited by 13
Wang, C., Ye, Q., Cao, Y., Tan, J., Wang, F., Jiang, J., & Cao, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.7351 · Cited by 12
ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
Nath, A., Cohen, A. L., & Bild, A. (2022) · Molecular Systems Biology · doi:10.15252/msb.202110558 · Cited by 14
Nasr, M., Farghaly, M., Elsaba, T. M., El‐Mokhtar, M. A., Radwan, R., Elsabahy, M., Abdelkareem, A., Fakhry, H., & Mousa, N. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.10.005 · Cited by 13
Bos, M. K., Smid, M., Sleijfer, S., & Martens, J. W. M. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00190 · Cited by 11
“E380Q activates ER to a lesser extent than other activating ESR1 mutations unrelated to APOBEC, which may explain the absence of strong selection in endocrine-resistant mBC of this particular mutation compared with other activating ESR1 mutations.(21) Apart from rare mutations in ESR1 and PIK3CA, we did observe compou…”
BackgroundVidal, M. J., Falato, C., Pascual, T., Sánchez-Bayona, R., Muñoz-Mateu, M., Cebrecos, I., González, X., Cortadellas, T., Vila, M. M., Luna, M. A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2460 · Cited by 12
“7, 9, 10).”
Borkar, S., Markus, F., Oetting, A., Schmidt, S., Vössing, C., Horst, D. A., Möbs, M., Braicu, E. I., Griesinger, F., Horling, K., et al. (2025) · Cancers · doi:10.3390/cancers17081266 · Cited by 12
Baek, M. L., Chang, J. T., & Echeverria, G. V. (2020) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-020-09470-3 · Cited by 11
“ctDNA sequencing often identified multipleESR1mutant alleles while only a single mutation was detected in each individual metastatic biopsy, suggesting that liquid biopsiesmay reflectESR1mutational heterogeneity from diverse metastatic lesions [123].”
BackgroundNext-Generation Estrogen Receptor–Targeted Therapeutics
Fernando, T. M., Moore, H. M., Wongchenko, M. J., & Metcalfe, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-013525 · Cited by 10
Xiong, S., Song, K., Xiang, H., & Luo, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116393 · Cited by 12
Moore, H. M., Savage, H. M., O'Brien, C. L., Zhou, W., Sokol, E. S., Goldberg, M. E., Metcalfe, C., Friedman, L. S., Lackner, M. R., & Wilson, T. R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0284 · Cited by 10
“40% (3, 4, 12) and are thus commonly pursued for clinical development of PI3K inhibitors.”
BackgroundSelf-citationLaws, M. J., Ziegler, Y., Shahoei, S. H., Dey, P., Kim, S. H., Yasuda, M. A., Park, B. H., Nettles, K. W., Katzenellenbogen, J. A., Nelson, E. R., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05629-y · Cited by 11
Du, Y., Li, N., Jiao, X., Li, K., & Yan, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171465 · Cited by 9
“12–15 Although the role of ESR1 mutations in predicting the efficacy of ET has been discussed extensively, no consensus has been reached to date.”
Li, S., Wang, B.-X., Li, Y., Lai, H., Liu, Y., & Jin, L. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13002 · Cited by 9
Westenend, P. J., Meurs, C. J. C., de Leeuw, B., & Akkers, R. C. (2024) · Cancers · doi:10.3390/cancers16173025 · Cited by 9
“Still, others have reported frequencies of between 0% and 3.5% [9,21,28,30].”
BackgroundInfluentialPARP-1 as a novel target in endocrine-resistant breast cancer
Zicarelli, A., Talia, M., Lainé, M., Lappano, R., Maggiolini, M., & Greene, G. L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03441-4 · Cited by 8
“Unfortunately, approximately 40% of patients develop resistance to ET [13–15].”
Liu, X., Davis, A. A., Xie, F., Gui, X., Chen, Y., Zhang, Q., Gerratana, L., Zhang, Y., Shah, A. N., Behdad, A., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06370-w · Cited by 9
Al-Aloosi, M., Prechtl, A. M., Chatterjee, P., Bernard, B. M., Kemp, C. J., Rosati, R., Diaz, R. L., Appleyard, L. R., Pereira, S. E., Rajewski, A. C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1267650 · Cited by 10
Schneeweiss, A., Brucker, S. Y., Huebner, H., Volmer, L. L., Hack, C. C., Seitz, K., Ruebner, M., Heublein, S., Thewes, V., Lüftner, D., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2286-6066 · Cited by 8
“Around 30 – 40% of tumors in patients with advanced endocrine-resistant breast cancer were found to have a mutation in the estrogen receptor gene ESR1 [21 – 23].”
Lin, W., Xu, Q.-N., Wang, H., & Li, X. (2017) · Breast Cancer · doi:10.1007/s12282-017-0770-3 · Cited by 7
“Retrospective analysis from the FERGI trial demonstrated that patients with ESR1 mutation did not have differential PFS in the fulvestrant plus pictilisib arm [33].”
MethodKojima, Y., Noguchi, E., Yoshino, T., Yagishita, S., Yazaki, S., Okuma, H. S., Nishikawa, T., Tanioka, M., Sudo, K., Shimoi, T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13122040 · Cited by 7
“To develop a detection system for ESR1 mutations using PNA-LNA PCR clamping, we focused on three common hotspot mutations in ESR1 (E380Q, Y537S, and D538G) that have been reported to be important for acquired resistance to endocrine therapy [7,24,25].”
MethodWang, C., Wang, J., Xue, X.-R., Shen, Y., Zou, B., Wang, S., Song, Q., & Zhou, G. (2022) · Journal of Analysis and Testing · doi:10.1007/s41664-022-00216-0 · Cited by 7
Lyu, D., Liu, B., Lan, B., Sun, X., Li, L., Zhai, J., Qian, H., & Ma, F. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.04.03 · Cited by 7
Frassoldati, A., Biganzoli, L., Bordonaro, R., Cinieri, S., Conte, P., Laurentis, M. D., Mastro, L. D., Gori, S., Lauria, R., Marchetti, P., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0942 · Cited by 7
Morganti, S., & Curigliano, G. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1720508 · Cited by 7
Masunaga, N., Kagara, N., Motooka, D., Nakamura, S., Miyake, T., Tanei, T., Naoi, Y., Shimoda, M., Shimazu, K., Kim, S. J., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.007 · Cited by 12
Morel, A., Masliah‐Planchon, J., Bataillon, G., Becette, V., Morel, C., Antonio, S., Girard, E., Bièche, I., Tourneau, C. L., & Kamal, M. T. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00398 · Cited by 7
“ESR1mutations were not reported to be associated with clinical resistance to fulvestrant.(13)”
BackgroundWu, Y. F., Li, Z., Lee, A. V., Oesterreich, S., & Luo, B. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07255-4 · Cited by 6
Shafer, P. W., Leung, W. K., Woods, M. L., Choi, J. M., Rodriguez-Plata, C. M., Maknojia, A., Mosquera, A., Somes, L. K., Joubert, J., Manliguez, A., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2023.12.002 · Cited by 6
ESR1 -Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Bonechi, F., Bacci, M., Lorito, N., Smiriglia, A., Subbiani, A., Pagliantini, E., Comito, G., Gangarossa, G., Duatti, A., Botty, R. E., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1339 · Cited by 6
Angus, L., Smid, M., Wilting, S. M., Bos, M. K., Steeghs, N., Konings, I. R. H. M., Tjan‐Heijnen, V. C. G., van Riel, J. M. G. H., van de Wouw, A. J., Cuppen, E. P. J. G., et al. (2023) · Cancers · doi:10.3390/cancers15174416 · Cited by 5
Padrão, N., Mayayo‐Peralta, I., & Zwart, W. T. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.10.008 · Cited by 6
Wang, C., Zeng, H., Zhang, L., Shen, Y., Zou, B., Wang, S., Song, Q., & Zhou, G. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.113959 · Cited by 5
HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer
Ando, Y., Miyadera, H., Bando, H., Hashimoto, S., Noguchi, E., & Hara, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13992-6 · Cited by 4
Pepe, F., Russo, G., Venetis, K., Scimone, C., Palumbo, L., Nacchio, M., di Giovanni, D., Sarracino, C., Tomaiuolo, I., Zulato, E., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100314 · Cited by 4
“Additionally, manual set up of dPCR threshold and visual inspection of NGS raw data may impact on VAF detectability across participating institutions; in particular below 1.0 % [41].”
InfluentialQureshi, Z. A., Jamil, A. R., Altaf, F., Siddique, R., Adilovic, E., Fatima, E., & Shah, S. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002293 · Cited by 6
“On the other hand, the PFS of patients receiving the SERD fulvestrant appears to be unaffected by the presence of ESR1 mutations [44,45] .”
BackgroundCurrent Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies
Tancredi, R. J., Sobhani, N., Catalano, M., Roviello, G., & Generali, D. (2025) · Genes · doi:10.3390/genes16040443 · Cited by 4
Cao, H., Sun, Y., Wang, L., Pan, Y., Li, Z., & Liang, Y. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105966 · Cited by 4
Identification of putative actionable alterations in clinically relevant genes in breast cancer
Kaur, P., Porras, T. B., Colombo, A., Ring, A., Lu, J. M., Kang, I. M., & Lang, J. E. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01522-7 · Cited by 4
Rajappa, S. J., Bajpai, J., Basade, M., Ganvir, M., Goswami, C., Murali, A., Rathi, A. K., Kaushal, V., Jain, S., Parikh, P. M., et al. (2018) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_121_18 · Cited by 4
“Preclinical studies have shown differences among ESR1 mutations in terms of sensitivity to endocrine therapies,[30] but clinical analyses have been underpowered and have not yet reached a consensus on this issue.[37-39] The panel opined that the current evidence on ESR1 mutations warrants prospective studies in which…”
BackgroundRojo, F., Guarneri, V., Fusco, N., Indraccolo, S., Bempt, I. V., Rocco, E. G., Sardinha, R., García-Murillas, I., Adorisio, R., Bragadin, A. B., et al. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00850-9 · Cited by 3
Ma, F., Liu, B., Yang, Y., Yi, Z., & Guan, X. (2017) · Cancer translational medicine · doi:10.4103/ctm.ctm_10_17 · Cited by 3
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer
Schmid, P. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.02.127 · Cited by 3
“ESR1-status does not appear to determine response to selective oestrogen receptor downregulators.(58,59) However, preclinical studies revealed relative resistance of the mutations to tamoxifen and fulvestrant but effective inhibition with high doses.”
Self-citationIgari, F., Tanaka, H., & Giuliano, A. E. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103725 · Cited by 4
Iwamoto, T., Niikura, N., Watanabe, K., Takeshita, T., Kikawa, Y., Kobayashi, K., Iwakuma, N., Okamura, T., Tada, H., Ozaki, S., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07144-2 · Cited by 3
“During fulvestrant treatment, ESR1 mutations did not show a consistent pattern of increase, and patients with ESR1 mutations had PFS similar to wild-type ESR1 [27].”
Fulvestrant in Management of Hormone Receptor-Positive Metastatic Breast Cancer
Shafaee, M. N., & Ellis, M. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0489 · Cited by 5
Clatot, F., Perdrix, A., Sefrioui, D., Sarafan‐Vasseur, N., & Fiore, F. D. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.09.002 · Cited by 3
Ji, H., Li, Y., Liu, Z., Tang, M. M., Zou, L., Su, F., Zhang, Y., Zhang, J., Li, H., Li, L., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00167 · Cited by 3
Heterogeneity of estrogen receptor based on 18F-FES PET imaging in breast cancer patients
Hao, W., Li, Y., Du, B., & Li, X. (2021) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00456-7 · Cited by 3
Okwor, V. C., Okwor, C. J., Ukwuoma, M., Mitha, S. B., & Nweke, M. (2025) · Medical Principles and Practice · doi:10.1159/000545264 · Cited by 3
“In contrast to AIs, which focus on oestrogen deprivation, SERM and SERD can still attach to the mutant receptor to inhibit its activity [12, 13].”
Characterization of ESR1 alterations in patients with breast and gynecologic cancers
Basu, G. D., Innis, P., Deem, A. K., Starodynov, A., Udhane, S. S., Szelinger, S., Wang, M., Lobello, J. R., Baehner, F. L., Jean–Paul De La, O., et al. (2026) · Breast Cancer Research · doi:10.1186/s13058-025-02217-0 · Cited by 3
Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
Hall, C. S., Sarli, V. N., Meas, S., & Lucci, A. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-0308-0 · Cited by 2
Therapeutic Strategies to Target Activating Estrogen Receptor α Mutations
Donahue, K., & Xu, W. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_15 · Cited by 2
Bos, M. K., Lam, S. W., Motta, G., Helmijr, J., Beaufort, C. M., de Jonge, E., Martens, J. W. M., Boven, E., Jansen, M. P. H. M., Jager, A., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06965-5 · Cited by 3
The next generation personalized models to screen hidden layers of breast cancer tumorigenicity
Afzali, F., Akbari, P., Naderi‐Manesh, H., & Gardaneh, M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05159-2 · Cited by 2
Place des CTC et de l’ADN circulant dans la prise en charge du cancer du sein
Allouchery, V., Augusto, L., & Clatot, F. (2019) · ONCOLOGIE · doi:10.3166/onco-2019-0035 · Cited by 2
Li, Y., Li, Y., Li, T., He, M., Chang, J., Cao, H., Luo, D., Lv, J., Zou, Y., Zheng, Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1527277 · Cited by 1
Choi, S., Jung, S., Kim, H. W., Lee, H., Jang, S., Baek, M., Yang, S., Choi, E. H., & Kim, S. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-21199-9 · Cited by 2
Alshehri, A. M., Altwairgi, A. K., AlTourah, A., Alwbari, A. M., Chehal, A. A., Calaud, F., Al-Hashem, H., Marashi, H., Elsamany, S., & Tirmazy, S. H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1706670 · Cited by 1
Al-Shamsi, H. O., Abdelwahed, N., Abdelwahab, S. İ., Hussein, M. M., Abyad, A. M., Rafii, S., Jaafar, H., Otsmane, S., Jabbar, D. A., Abdellatif, H., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16121790 · Cited by 1
“In ESR1-mutated disease without dominant PI3K pathway activation, oral selective estrogen receptor degraders such as elacestrant represent evidence-supported options [7,15–17].”
La biopsie liquide, une nouvelle opportunité pour l’oncologie personnalisée
Astaras, C., Dolcan, A., Bisig, B., & Zaman, K. (2018) · JMIG · doi:10.53738/revmed.2018.14.607.1028 · Cited by 1
Zhang, X., Tian, Y., Mo, D., Chen, W., Ding, Y., Yang, Y., & Li, X. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/175816 · Cited by 1
Prat, A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732766665.793560858 · Cited by 1
Circulating Free Tumor DNA (ctDNA): The Real-Time Liquid Biopsy
Kyker‐Snowman, K., & Park, B. H. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-50956-3_6
Chudnovsky, Y., Kumar, R. D., Schrock, A. B., Connelly, C. F., Gowen, K. A., Frampton, G. M., Erlich, R., Stephens, P. J., Miller, V. A., Ross, J. S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00037 · Cited by 1
Yao, H., Wu, G., Das, S., MacKenzie, C. J., Gao, H., Rimkunas, V. M., Zhang, Z., Ferro, S. L., Roden, A., Korpal, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/598847
Mutations du gène ESR1 : du fondamental à la clinique
Massard, V., Harlé, A., Uwer, L., & Merlin, J. (2019) · ONCOLOGIE · doi:10.3166/onco-2019-0027
Королева, И. А., & Валериевич, К. М. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-9-62-72
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating MutationsPreprint
Jeselsohn, R. M., Bergholz, J. S., Pun, M. J., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Buchwalter, G., Feiglin, A., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3155601
Wilson, B. E., & Cescon, D. W. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000786
“Although ESR1 mutations are a recognized resistance mechanism for patients receiving AIs or tamoxifen, ESR1 mutations as a class impart less clinical resistance to Fulvestrant [7], and patients with ESR1 mutations treated with Fulvestrant have improved survival compared to those treated with AIs [8 & ].”
BackgroundInfluentialVicente, L. W., Arai, L. M. G., Mafacioli, J. M. S., Sobrinho, R. A., Lima, M. C. R. A., & Francisco, J. F. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n6-059
Tumor genetics and individualized therapy
Hlevnjak, M. (2022) · Die Gynäkologie · doi:10.1007/s00129-022-04931-8
Ross, D. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_8
Schettini, F., Buono, G., Giuliano, M., Arpino, G., & Placido, S. D. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_10
Awada, A. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732292489.793559045
Effective treatment based on monitoring bESR1 mutations
Hirai, H., Shimomura, A., Kitagawa, D., & Shimizu, C. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00737-9
van der Ploeg, P. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230113pp
Tolaney, S. M., Toi, M., Neven, P., Sohn, J., Grischke, E., Llombart‐Cussac, A., Soliman, H. H., Wang, H., Wijayawardana, S. R., Jansen, V. M., et al. (2023) · doi:10.1158/1078-0432.c.6532329
Li, Z., Wu, Y., Yates, M. E., Tasdemir, N., Bahreini, A., Chen, J., Levine, K. M., Priedigkeit, N., Nasrazadani, A., Ali, S., et al. (2023) · doi:10.1158/0008-5472.c.6513817
Shanthala, S., Amirtham, U., Lokesh, K. N., Jacob, L. A., & Babu, G. (2023) · South Asian Journal of Cancer · doi:10.1055/s-0043-1775806
Additional file 1 of Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling
Lü, J., Zhao, Q., Guo, Y., Li, D., Xie, H., Liu, C., Hu, X., Liu, S., Hou, Z., Wei, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671401
Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer
Takeshita, T., & Iwase, H. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_251
Advances in Targeted Therapy and Biomarker Research for Endocrine-Related Cancers
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5834-8
Schneeweiss, A., Brucker, S. Y., Huebner, H., Volmer, L. L., Hack, C. C., Seitz, K., Ruebner, M., Heublein, S., Thewes, V., Lüftner, D., et al. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2453-4561
Molecular Testing in Breast Cancer
Vougiouklakis, T., & Ross, D. S. (2025) · Surgical pathology clinics · doi:10.1016/j.path.2025.05.003
Srinivasan, N. (2025) · Research Square · doi:10.21203/rs.3.rs-8227309/v1
Additional file 3 of Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling
Lü, J., Zhao, Q., Guo, Y., Li, D., Xie, H., Liu, C., Hu, X., Liu, S., Hou, Z., wei, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671410
Additional file 2 of Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling
Lü, J., Zhao, Q., Guo, Y., Li, D., Xie, H., Liu, C., Hu, X., Liu, S., Hou, Z., wei, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671407
Luen, S. J. (2021) · Minerva Access (University of Melbourne) · Cited by 1
Moore, M. (2020) · eScholarship@McGill (McGill) · doi:10.82308/29176
Verma, K. K. (2026) · Surgical and Experimental Pathology · doi:10.1186/s42047-026-00220-z
“…resistance, emerging evidence indicates that ESR1 mutations may fundamentally alter tumor biology, including immune microenvironment characteristics (Dustin et al. 2019; “ESR1 Mutations in Hormone Receptor Positive Breast Cancer,” n.d.; Li et al. 2022a; Lopez et al. 2025; Spoerke et al. 2016).”
Strategic Treatment Sequencing and Novel Approaches in 2L+ ER+/HER2- Metastatic Breast Cancer
Scott, B. (2026) · EMJ Oncology · doi:10.33590/emjoncol/gfwm9676
The effect of lncRNA UCA1 on PI3K/AKT/mTOR signaling in doxorubicin-resistant ER+ breast cancer
Namalir, G. (2025) · Hitit University Institutional Repository
Amiguet, E. (2009) · theses.fr (ABES) · doi:10.70675/a6a1caeez288cz462dz9783z62861aa7d34d
Pham, T. H. (2020) · theses.fr (ABES) · doi:10.70675/81c56b74z437dz454ez84f6za618854f7b95 · Cited by 1
Warwas, K. M., Volckmar, A., Kazdal, D. N., Ball, M., Smetanay, K., Maurer, C., Fremd, C., Sych, L., Thewes, V., Budczies, J., et al. (2026) · Breast Care · doi:10.1159/000552643
Metadata
- Authors
- Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., Amler, L. C., Hampton, G. M., Johnston, S., Krop, I., Schmid, P., & Lackner, M. R.
- Affiliations
- Genentech (US)
- Royal Marsden NHS Foundation Trust (GB)
- Dana-Farber Cancer Institute (US)
- Queen Mary University of London (GB)
- Corresponding author
- Lackner, Mark R.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-05-13
- Volume
- 7
- Issue
- 1
- Pages
- 11579-11579
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4869259
- OpenAlex
- W2374277491
- Cited by
- 309
- References
- 41
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 14 · 2023: 30 · 2022: 27 · 2021: 37 · 2020: 28 · 2019: 42 · 2018: 36 · 2017: 41 · 2016: 12
- FWCI
- 39.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- ESR1 mutations, fulvestrant, PIK3CA mutation, circulating tumor DNA, clonal evolution, treatment resistance, pan-PI3K inhibitor, progression-free survival, luminal A
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, DNA Mutational Analysis, DNA, Neoplasm, Estradiol, Estrogens, Female, Humans, Indazoles, Middle Aged, Mutation, Sulfonamides, Disease-Free Survival, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Estrogen Receptor alpha, Class I Phosphatidylinositol 3-Kinases, Estrogen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.